ARS Pharmaceuticals (NASDAQ:SPRY) Coverage Initiated by Analysts at Northland Securities

Northland Securities assumed coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY) in a research note issued to investors on Thursday, Marketbeat.com reports. The brokerage issued an outperform rating and a $25.00 price target on the stock.

A number of other brokerages have also weighed in on SPRY. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research report on Wednesday, January 21st. Zacks Research raised ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, Leerink Partners set a $26.00 target price on ARS Pharmaceuticals and gave the stock an “outperform” rating in a research report on Tuesday, March 10th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, ARS Pharmaceuticals has an average rating of “Hold” and a consensus target price of $28.25.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ:SPRY opened at $8.27 on Thursday. The company has a quick ratio of 7.06, a current ratio of 7.28 and a debt-to-equity ratio of 1.47. ARS Pharmaceuticals has a twelve month low of $6.66 and a twelve month high of $18.90. The stock’s 50 day moving average is $8.87 and its 200-day moving average is $9.62. The firm has a market capitalization of $821.19 million, a price-to-earnings ratio of -4.73 and a beta of 0.86.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its earnings results on Monday, March 9th. The company reported ($0.42) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.42). ARS Pharmaceuticals had a negative return on equity of 100.29% and a negative net margin of 203.25%.The company had revenue of $28.09 million for the quarter, compared to analyst estimates of $25.58 million. Sell-side analysts forecast that ARS Pharmaceuticals will post -0.55 EPS for the current fiscal year.

Institutional Investors Weigh In On ARS Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. CWM LLC grew its holdings in ARS Pharmaceuticals by 243.7% during the third quarter. CWM LLC now owns 2,547 shares of the company’s stock worth $26,000 after buying an additional 1,806 shares in the last quarter. Torren Management LLC bought a new stake in ARS Pharmaceuticals during the fourth quarter worth $32,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in ARS Pharmaceuticals by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock worth $56,000 after buying an additional 982 shares in the last quarter. Osterweis Capital Management Inc. bought a new stake in ARS Pharmaceuticals during the fourth quarter worth $65,000. Finally, Russell Investments Group Ltd. grew its holdings in ARS Pharmaceuticals by 197.5% during the third quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company’s stock worth $67,000 after buying an additional 4,427 shares in the last quarter. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.